Recently, 2Y-Biopharma, a wholly owned subsidiary of Shanghai Haoyuan Chemexpress Co, Ltd. ("ChemExpress")  for drug product GMP manufacturing, successfully completed a Pre-Approval Inspection (PAI) conducted by the U.S. Food and Drug Administration (FDA), with no Form 483 observations.